Agios/$AGIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Agios
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Ticker
$AGIO
Sector
Primary listing
Employees
487
Headquarters
Website
Agios Metrics
BasicAdvanced
$2.1B
3.31
$11.13
0.73
-
Price and volume
Market cap
$2.1B
Beta
0.73
52-week high
$59.29
52-week low
$23.42
Average daily volume
953K
Financial strength
Current ratio
14.479
Quick ratio
13.406
Long term debt to equity
2.276
Total debt to equity
3.56
Profitability
EBITDA (TTM)
-456.284
Gross margin (TTM)
-694.56%
Net profit margin (TTM)
1,590.42%
Operating margin (TTM)
-1,129.13%
Effective tax rate (TTM)
6.37%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-25.71%
Return on equity (TTM)
64.05%
Valuation
Price to earnings (TTM)
3.306
Price to revenue (TTM)
51.613
Price to book
1.56
Price to tangible book (TTM)
1.56
Price to free cash flow (TTM)
-5.158
Free cash flow yield (TTM)
-19.39%
Free cash flow per share (TTM)
-7.131
Growth
Revenue change (TTM)
30.57%
Earnings per share change (TTM)
-271.34%
3-year revenue growth (CAGR)
85.40%
10-year revenue growth (CAGR)
-8.18%
3-year earnings per share growth (CAGR)
18.36%
10-year earnings per share growth (CAGR)
20.96%
What the Analysts think about Agios
Analyst ratings (Buy, Hold, Sell) for Agios stock.
Bulls say / Bears say
PYRUKYND net revenue for the second quarter grew 45% YoY to $12.5 million, showing strong market adoption in pyruvate kinase deficiency patients.
Cash, cash equivalents, and marketable securities totaling $1.3 billion as of June 30, 2025, provide over three years of operational funding for next-generation programs.
Signed a distribution agreement with Avanzanite Bioscience to market PYRUKYND across Europe and the U.K., increasing the addressable market in a cost-efficient way.
Q2 2025 net loss of $112 million is much greater than PYRUKYND revenue, highlighting a long road to profitability.
Research and Development expenses increased to $91.9 million (+19% YoY) and Selling, General & Administrative expenses rose to $45.9 million (+29% YoY), increasing cash burn risk.
Approval of PYRUKYND for thalassemia depends on the FDA’s PDUFA decision on September 7, 2025; any delay or unfavorable outcome could slow revenue growth.
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
Agios Financial Performance
Revenues and expenses
Agios Earnings Performance
Company profitability
Agios News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Agios stock?
Agios (AGIO) has a market cap of $2.1B as of September 14, 2025.
What is the P/E ratio for Agios stock?
The price to earnings (P/E) ratio for Agios (AGIO) stock is 3.31 as of September 14, 2025.
Does Agios stock pay dividends?
No, Agios (AGIO) stock does not pay dividends to its shareholders as of September 14, 2025.
When is the next Agios dividend payment date?
Agios (AGIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Agios?
Agios (AGIO) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.